Want to see JP:4594 full AI Analyst Report?
4594 Stock Chart & Stats
¥48.00
¥1.00(2.27%)
At close: 4:00 PM EST
¥48.00
¥1.00(2.27%)
Day’s Range― - ―
52-Week Range¥43.00 - ¥105.00
Previous CloseN/A
Volume188.00K
Average Volume (3M)2.78M
Market Cap
¥7.22B
Enterprise Value¥4.81K
Total Cash (Recent Filing)¥2.16B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.97
Shares Outstanding138,891,300
10 Day Avg. Volume4,086,650
30 Day Avg. Volume2,782,203
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.25
Price to Sales (P/S)91636.06
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces refinancing pressure and interest-related strain, giving BrightPath more financial flexibility while it develops therapies. This balance-sheet strength does not solve the cash-burn issue, but it provides a useful buffer against near-term balance-sheet stress.
Positive Gross MarginPositive gross margin indicates that reported revenue has generated value above direct costs in the latest periods, and narrower losses versus 2021 suggest some improvement from prior lows. However, the benefit remains limited until revenue becomes more consistent and operating costs are better absorbed.
Balance-Sheet Asset BufferA relatively substantial asset and equity base can support ongoing research activity and provide capacity to manage development programs. This buffer may extend strategic flexibility over the next several months, although continued losses could reduce it through further burn or equity issuance.
Bears Say
Revenue Volatility And CollapseThe sharp revenue decline and history of volatility indicate weak and uneven commercial traction, potentially reflecting dependence on irregular milestone or other income. Such an unstable revenue base makes it difficult to fund R&D internally or establish a dependable operating model.
Persistent Operating LossesLarge recurring EBIT and net losses show that operating expenses, including research and development, remain far above the company’s revenue base. Without stronger product or partnership income, continued losses could constrain development plans and increase reliance on external financing.
Sustained Cash BurnConsistently negative operating and free cash flow means BrightPath is not currently self-funding its activities. The lack of a durable improvement trend raises ongoing runway and dilution risk, even with low leverage, because research programs require continued funding before commercial returns emerge.
BrightPath Biotherapeutics Co.Ltd. News
4594 FAQ
What was BrightPath Biotherapeutics Co.Ltd.’s price range in the past 12 months?
BrightPath Biotherapeutics Co.Ltd. lowest stock price was ¥43.00 and its highest was ¥105.00 in the past 12 months.
What is BrightPath Biotherapeutics Co.Ltd.’s market cap?
BrightPath Biotherapeutics Co.Ltd.’s market cap is ¥7.22B.
When is BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date?
BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 80 days.
How were BrightPath Biotherapeutics Co.Ltd.’s earnings last quarter?
BrightPath Biotherapeutics Co.Ltd. released its earnings results on Aug 14, 2026. The company reported -¥3.82 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is BrightPath Biotherapeutics Co.Ltd. overvalued?
According to Wall Street analysts BrightPath Biotherapeutics Co.Ltd.’s price is currently Overvalued.
Does BrightPath Biotherapeutics Co.Ltd. pay dividends?
BrightPath Biotherapeutics Co.Ltd. does not currently pay dividends.
What is BrightPath Biotherapeutics Co.Ltd.’s EPS estimate?
BrightPath Biotherapeutics Co.Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BrightPath Biotherapeutics Co.Ltd. have?
BrightPath Biotherapeutics Co.Ltd. has 138,891,300 shares outstanding.
What happened to BrightPath Biotherapeutics Co.Ltd.’s price movement after its last earnings report?
BrightPath Biotherapeutics Co.Ltd. reported an EPS of -¥3.82 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.961%.
Which hedge fund is a major shareholder of BrightPath Biotherapeutics Co.Ltd.?
Currently, no hedge funds are holding shares in JP:4594
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrightPath Biotherapeutics Co.Ltd.
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
CellSource Co., Ltd.
―
StemCell Institute
―
CellSeed Inc.
―